ConductScience.org, home

Paper26311728

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.

Garcia-Murillas I and 14 others. Sci Transl Med, 2015. Cited by 994 papers, by iCite.

Cite this record

ConductScience Library. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Papers, record 26311728. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26311728

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.
PubMed
Journal
Sci Transl Med
PubMed
Year
2015
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
994
iCite
Relative citation ratio, by iCite
28.1
iCite
Revised in PubMed
2025-05-29
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Garcia-Murillas IIsaac
2Schiavon GGaia
3Weigelt BBritta
4Ng CCharlotte
5Hrebien SSarah
6Cutts RJRosalind J
7Cheang MMaggie
8Osin PPeter
9Nerurkar AAshutosh
10Kozarewa IIwanka
11Garrido JAJavier Armisen
12Dowsett MMitch
13Reis-Filho JSJorge S
14Smith IEIan E
15Turner NCNicholas C

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
DNA, NeoplasmMajor topic
MutationMajor topic
Female
High-Throughput Nucleotide Sequencing
Humans
Neoplasm, Residual
Precision Medicine
Recurrence

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
16642Cancer Research UKUnited KingdomPubMed
C30746/A16642Cancer Research UKUnited KingdomPubMed

Source PubMed

Download CSV of grants

Trials11

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT02797652Clinical Application of CTDNA in Operable Breast Cancer PatientsBackgroundClinicalTrials.gov
NCT03312374ctDNA as a Prognostic Marker for Postoperative Relapse in Early and Intermediate Stage Colorectal CancerResultsClinicalTrials.gov
NCT04228614Evaluation of Somatic Mutation Spectrum as Biomarker for Survival Outcome in Chinese CRCBackgroundClinicalTrials.gov
NCT04985266
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
BackgroundClinicalTrials.gov
NCT05058183Safe De-escalation of Chemotherapy for Stage 1 Breast CancerBackgroundClinicalTrials.gov
NCT05079074Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast CancerBackgroundClinicalTrials.gov
NCT05131243the Role of ctDNA in Predicting the Recurrence Risk of Colorectal CancerBackgroundClinicalTrials.gov
NCT05167604Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLCResultsClinicalTrials.gov
NCT05227261Early Detection of Five Common Cancers Using the ctDNA Analysing TestBackgroundClinicalTrials.gov
NCT05408897Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRDResultsClinicalTrials.gov
NCT06613516Effect of Capivasertib on ctDNA in ER Positive Breast CancerBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections4

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in26311727Does molecular monitoring matter in early-stage breast cancer?https://conductscience.org/library/papers/26311727PubMed
Comment in26370605Breast cancer: Tracking ctDNA to evaluate relapse risk.https://conductscience.org/library/papers/26370605PubMed
Comment in27868036The state of the art in prediction of breast cancer relapse using cell-free circulating tumor DNA liquid biopsies.https://conductscience.org/library/papers/27868036PubMed
Comment in28149904What the blood knows: interrogating circulating tumor DNA to predict progression of minimal residual disease in early breast cancer.https://conductscience.org/library/papers/28149904PubMed

Download CSV of comments and corrections

Cited by665

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 994 citations.

PMIDTitleJournalYearIn PapersSource
42958365Dynamic ctDNA-MRD in breast cancer: subtype-specific implications for perioperative decision-making, postoperative surveillance, and MRD-guided therapy.World J Surg Oncol2026https://conductscience.org/library/papers/42958365PubMed
42953478Cellular origins and evolutionary dynamics of plasma cfDNA in solid tumors: integrating germline, tumor-derived, and hematopoietic variation for MRD and treatment guidance.Front Cell Dev Biol2026https://conductscience.org/library/papers/42953478PubMed
42889542Inflammatory breast cancer among advanced breast malignancies: diagnostic, microenvironmental, and therapeutic challenges of the rare amongst the common.Front Oncol2026https://conductscience.org/library/papers/42889542PubMed
42884096Dynamic Immune Responsiveness in Breast Cancer: Tumor Microenvironment Plasticity, Therapeutic Timing, and Clinical Translation.Int J Mol Sci2026https://conductscience.org/library/papers/42884096PubMed
42795008Circulating Tumor DNA-Based Molecular Residual Disease in Early-Stage Non-Small-Cell Lung Cancer: Biology, Assays, and the Path Toward MRD-Guided Care.Cancers (Basel)2026https://conductscience.org/library/papers/42795008PubMed
42786286Localized immunotherapy via dissolving microneedles for the prevention of breast cancer recurrence.Drug Deliv Transl Res2026https://conductscience.org/library/papers/42786286PubMed
42737612Circulating Tumor DNA and Circulating Tumor Cells in Liquid Biopsy as Post-Treatment Prognostic Biomarkers in Early Breast Cancer: A Systematic Review and Meta-Analysis.Int J Mol Sci2026https://conductscience.org/library/papers/42737612PubMed
42728989Method development for pancreatic and ovarian cancer baseline ctDNA detection and measurable residual disease monitoring.Open Res Eur2026https://conductscience.org/library/papers/42728989PubMed
42727049Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab.JCO Precis Oncol2026https://conductscience.org/library/papers/42727049PubMed
42724567Assessing the utility of ctDNA as a prognostic marker in advanced ER-positive/HER2-negative breast cancer.Transl Cancer Res2026https://conductscience.org/library/papers/42724567PubMed
42713037Circulating tumor DNA-based minimal residual disease-guided adjuvant therapy in solid tumors: Current evidence, clinical trial frameworks, and future directions.Chin J Cancer Res2026https://conductscience.org/library/papers/42713037PubMed
42682436NED-oriented oncology in metastatic breast cancer: a hypothesis-driven framework integrating the tumor immune microenvironment, antibody-drug conjugates, and metastasis-directed therapy.Front Oncol2026https://conductscience.org/library/papers/42682436PubMed
42645355Evolution of the Use of Circulating DNA as a Biomarker in Neoadjuvant Therapy of Breast Cancer.Curr Oncol2026https://conductscience.org/library/papers/42645355PubMed
42567927Charting intratumor heterogeneity from bench to bedside.Nat Cancer2026https://conductscience.org/library/papers/42567927PubMed
42558411Advances and challenges in biomarker guided management of triple-negative breast cancer in the era of neoadjuvant chemo-immunotherapy.Front Oncol2026https://conductscience.org/library/papers/42558411PubMed
42512406Non-Invasive Diagnosis of Early Breast Cancer: Current and Emerging Liquid Biopsy Biomarkers.Cancers (Basel)2026https://conductscience.org/library/papers/42512406PubMed
42509573Circulating tumor DNA precision oncology enables effective and sensitive molecular diagnostics and actionable target detection in pediatric solid tumors - the INFORM experience.Genome Med2026https://conductscience.org/library/papers/42509573PubMed
42500286
Development and internal validation of a radiomics-clinical combined model for predicting axillary pathological complete response in clinically node-positive breast cancer patients after neoadjuvant chemotherapy.
Front Oncol2026https://conductscience.org/library/papers/42500286PubMed
42472109The role of serologic biomarkers "liquid biopsy" in the fight against breast cancer: From biological foundations to clinical impact.iScience2026https://conductscience.org/library/papers/42472109PubMed
42455255Optimizing Extended Adjuvant Endocrine Therapy in Early HR+/HER2- Breast Cancer: The Emerging Role of Genomic Assays and ctDNA MRD.Adv Ther2026https://conductscience.org/library/papers/42455255PubMed

See all 665 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26311728

GET https://conductscience.org/api/papers/v1/26311728/cited_by?page=2